Clearing hurdles in anticoagulation therapy: drug trends in cardiology.
The hurdles that need to be cleared when initiating therapy with the novel anticoagulants (NOACs) are the following, says Prof Sylvia Haas: 'The different dosing regimens, depending on whether these agents are being used for venous thromboembolism (VTE) treatment or stroke prevention. The practical usage of them. The management of bleeding associated with their use.' She was speaking at a meeting held in Johannesburg in late July as a guest of Bayer Healthcare.